Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 364

1.

A distinct subpopulation within CD133 positive brain tumor cells shares characteristics with endothelial progenitor cells.

Choi SA, Wang KC, Phi JH, Lee JY, Park CK, Park SH, Kim SK.

Cancer Lett. 2012 Nov 28;324(2):221-30. doi: 10.1016/j.canlet.2012.05.026. Epub 2012 May 28.

PMID:
22652175
2.

CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.

Rocco A, Liguori E, Pirozzi G, Tirino V, Compare D, Franco R, Tatangelo F, Palaia R, D'Armiento FP, Pollastrone G, Affuso A, Bottazzi EC, Masone S, Persico G, Nardone G.

J Cell Physiol. 2012 Jun;227(6):2686-93. doi: 10.1002/jcp.23013.

PMID:
21898409
3.

Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients.

Ahn JB, Rha SY, Shin SJ, Jeung HC, Kim TS, Zhang X, Park KH, Noh SH, Roh JK, Chung HC.

Cancer Lett. 2010 Feb 1;288(1):124-32. doi: 10.1016/j.canlet.2009.06.031. Epub 2009 Jul 19.

PMID:
19619937
4.

Endothelial precursor cells promote angiogenesis in hepatocellular carcinoma.

Sun XT, Yuan XW, Zhu HT, Deng ZM, Yu DC, Zhou X, Ding YT.

World J Gastroenterol. 2012 Sep 21;18(35):4925-33.

5.

Endothelial progenitor cells derived from CD34+ cells form cooperative vascular networks.

Guo S, Cheng Y, Ma Y, Yang X.

Cell Physiol Biochem. 2010;26(4-5):679-88. doi: 10.1159/000322335. Epub 2010 Oct 29.

6.

CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.

He J, Liu Y, Zhu T, Zhu J, Dimeco F, Vescovi AL, Heth JA, Muraszko KM, Fan X, Lubman DM.

Mol Cell Proteomics. 2012 Jun;11(6):M111.010744. doi: 10.1074/mcp.M111.010744. Epub 2011 Dec 27.

7.

Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.

Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G.

Clin Cancer Res. 2009 Jul 1;15(13):4299-311. doi: 10.1158/1078-0432.CCR-08-1883. Epub 2009 Jun 9.

8.

[Preliminary studies on cell derivation of neovascularization in human glioma and its functional evaluation].

Fei XF, Zhang QB, Dong J, Wang AD, Wang ZM, Huang Q.

Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):726-31. Chinese.

PMID:
22335902
9.

CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity.

Shi CJ, Gao J, Wang M, Wang X, Tian R, Zhu F, Shen M, Qin RY.

World J Gastroenterol. 2011 Jun 28;17(24):2965-71. doi: 10.3748/wjg.v17.i24.2965.

10.

NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.

Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, Nikkhah G, Dimeco F, Piccirillo S, Vescovi AL, Eberhart CG.

Stem Cells. 2010 Jan;28(1):5-16. doi: 10.1002/stem.254.

11.

The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.

Le H, Zeng F, Xu L, Liu X, Huang Y.

Mol Med Rep. 2013 Nov;8(5):1511-8. doi: 10.3892/mmr.2013.1667. Epub 2013 Sep 4.

PMID:
24008862
12.

Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties.

Navarro-Alvarez N, Kondo E, Kawamoto H, Hassan W, Yuasa T, Kubota Y, Seita M, Nakahara H, Hayashi T, Nishikawa Y, Hassan RA, Javed SM, Noguchi H, Matsumoto S, Nakaji S, Tanaka N, Kobayashi N, Soto-Gutierrez A.

Cell Transplant. 2010;19(6):865-77. doi: 10.3727/096368910X508997. Epub 2010 Jun 29.

13.

CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.

Bexell D, Gunnarsson S, Siesjö P, Bengzon J, Darabi A.

Int J Cancer. 2009 Jul 1;125(1):15-22. doi: 10.1002/ijc.24306.

14.
15.

CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).

Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, Iwasaki H, Emoto M.

Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.

16.

Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.

Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R, Larocca LM.

Cancer. 2011 Jan 1;117(1):162-74. doi: 10.1002/cncr.25581. Epub 2010 Aug 30. Erratum in: Cancer. 2016 Oct;122(19):3090.

17.

Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.

Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, Kang J, Assanah M, McKhann GM, Sisti MB, McCormick PC, Canoll P, Bruce JN.

Neurosurgery. 2008 Feb;62(2):505-14; discussion 514-5. doi: 10.1227/01.neu.0000316019.28421.95.

PMID:
18382330
18.

Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors.

Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, De Buyzere ML, Gillebert TC, Plum J, Vandekerckhove B.

Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1572-9. Epub 2007 May 10.

19.

CD133+ niches and single cells in glioblastoma have different phenotypes.

Christensen K, Schrøder HD, Kristensen BW.

J Neurooncol. 2011 Aug;104(1):129-43. doi: 10.1007/s11060-010-0488-y. Epub 2010 Dec 24.

PMID:
21184132
20.

Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.

Chen KL, Pan F, Jiang H, Chen JF, Pei L, Xie FW, Liang HJ.

Clin Exp Metastasis. 2011 Dec;28(8):751-63. doi: 10.1007/s10585-011-9407-7. Epub 2011 Jul 13.

PMID:
21750907

Supplemental Content

Support Center